泰恩康(301263.SZ):全資子公司收到富馬酸盧帕他定片藥品註冊證書
格隆匯2月7日丨泰恩康(301263.SZ)公佈,公司全資子公司山東華鉑凱盛生物科技有限公司於近日收到國家藥品監督管理局簽發的富馬酸盧帕他定片《藥品註冊證書》。
富馬酸盧帕他定是一種長效抗組胺劑,通過選擇性拮抗組胺H1受體發揮作用,主要用於成人和青少年(12歲以上)過敏性鼻炎和蕁麻疹的對症治療。富馬酸盧帕他定具有抗過敏的特性,表現為對因免疫系統或非免疫系統刺激引起的肥大細胞脱落顆粒作用的抑制和對炎性介質細胞因子釋放的抑制作用。此外,在體外和體內試驗中,富馬酸盧帕他定還具有拮抗血小板活化因子的作用,通過拮抗血小板活化因子降低血管通透性增加,進一步減少流鼻涕、鼻塞、血管性水腫等症狀。
根據米內網數據顯示,2023年在中國城市公立醫院和縣級公立醫院、城市社區中心和鄉鎮衞生院、城市實體藥店和網上藥店市場,富馬酸盧帕他定片的合計銷售額超過4.0億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.